Cardiac fibroblast (CF) differentiation plays a crucial role in cardiac fibrosis, which is a
specific manifestation distinguishing pathological cardiac hypertrophy from physiological …

Background: Shortly after birth, cardiomyocytes exit the cell cycle and cease proliferation. At
present, the regulatory mechanisms for this loss of proliferative capacity are poorly …

The poly (rC)‐binding protein 2 (PCBP2) is currently reported to inhibit cardiac hypertrophy.
However, how PCBP2 is regulated at transcriptional level remains unknown. Here, we show …

Cardiac hypertrophy is a common pathological alteration in heart disease, which has been
reported to be connected with serine/threonine protein phosphatases that control the …

The Angiotensin II/transforming growth factor-β1 (AngII/TGF-β1) signal axis is an important
regulatory pathway for atrial fibrosis, which can contribute to atrial fibrillation (AF). Fused in …

Aims The activation of cardiac fibroblasts (CFs) leads to overproduction of collagens and
subsequently cardiac fibrosis. However, the regulatory mechanism of CF function in the …

Cytokine-like 1 (Cytl1) is a secreted protein that is involved in diverse biological processes.
A comparative modeling study indicated that Cytl1 is structurally and functionally similar to …

Differentiation and activation of fibroblasts into myofibroblasts which express α-smooth
muscle actin (α-SMA) are essential for wound healing and tissue repair. Change in fibroblast …

Congenital heart disease (CHD) is a worldwide health problem, particularly in young
populations. In spite of the advancement and progress in medical research and technology …

Background: Pathological cardiac fibrosis and hypertrophy, the common features of left
ventricular remodeling, often progress to heart failure. Forkhead box transcription factor P1 …